NCT03764293: A trial that was reported late by Jiangsu HengRui Medicine Co., Ltd.
This trial has reported, although it was 275 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03764293 |
|---|---|
| Title | A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 10, 2019 |
| Completion date | Feb. 8, 2022 |
| Required reporting date | Feb. 8, 2023, midnight |
| Actual reporting date | Nov. 10, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 275 |